echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Sanofi cuts off two early-stage tumor monoclonal antibodies after terminating cooperation with Sangamo cell therapy

    Sanofi cuts off two early-stage tumor monoclonal antibodies after terminating cooperation with Sangamo cell therapy

    • Last Update: 2022-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationAspirin

    Sanofi axed two more cancer-preventing monoclonal antibodies in Phase 1 clinical trials, weeks after terminating a cell therapy partnership with Sangamo


    The large French pharmaceutical company disclosed the axed items during its full-year 2021 earnings call on February 4, 2022


    As Sanofi CEO Paul Hudson described in December 2019, the two drug candidates are part of Sanofi's push into the next cycle of its drug development, but the cuts could be nearly as bad for the company's pipeline.


    SAR439459, an anti-TGFb therapy


    Sanofi's trial entry for SAR442085 was updated on January 14 and listed the trial status as recruiting


    The news comes just weeks after Sanofi said it would end its cell therapy agreement with Sangamo


    Reference: Sanofi ends 2 phase 1 cancer assets weeks after axing Sangamo deal

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.